BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Has Consensus Target Price of $89.17

Key Points

• BioMarin has a “Moderate Buy” consensus rating from 24 analysts, with 15 buy ratings, seven holds, one sell and one strong buy. The average 12-month price target is $89.17, versus the reported share price of $60.04.
• The company exceeded quarterly expectations, reporting $1.20 in EPS versus the $0.95 consensus and revenue of $989.71 million versus $932.03 million expected. Revenue increased 20% year over year.
• Institutional investors own 98.71% of BioMarin’s stock, while shares trade at a high price-to-earnings ratio of 162.27 and have recently been below their 50-day moving average.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-four brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, fifteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $89.17.

A number of research analysts recently issued reports on BMRN shares. Royal Bank Of Canada dropped their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a report on Tuesday, July 7th. Barclays boosted their target price on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the stock an "overweight" rating in a report on Monday, August 17th. HC Wainwright restated a "neutral" rating and issued a $60.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 10th. Oppenheimer raised their price target on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an "outperform" rating in a research note on Friday, August 7th. Finally, Citigroup lifted their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, July 16th.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in BMRN. Parkside Financial Bank & Trust increased its position in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock worth $26,000 after buying an additional 187 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BioMarin Pharmaceutical during the second quarter worth $39,000. Keating Financial Advisory Services Inc. acquired a new position in BioMarin Pharmaceutical in the second quarter valued at $56,000. Wick Capital Partners LLC acquired a new position in BioMarin Pharmaceutical in the fourth quarter valued at $73,000. Finally, Parallel Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 33.9% in the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock valued at $100,000 after buying an additional 448 shares during the period. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 0.3%

NASDAQ BMRN opened at $60.04 on Thursday. The company has a market cap of $11.62 billion, a price-to-earnings ratio of 162.27, a price-to-earnings-growth ratio of 0.43 and a beta of 0.24. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The business's fifty day moving average is $64.18 and its 200 day moving average is $58.65.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to analysts' expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business's revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, sell-side analysts expect that BioMarin Pharmaceutical will post 4.1 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.